Macaques co-immunized with SIVgag/pol-HIVenv and IL-12 plasmid have increased cellular responses

Journal of Medical Primatology

Volumn 36, Issue 4-5, 2007, Pages 276-284

  Robinson, T M ^a   Sidhu, M K ^b   Pavlakis, G N ^c   Felber, B K ^c   Silvera, P ^d   Lewis, M G ^e   Eldridge, J ^b   Weiner, D B ^f   Boyer, Jean D ^f  

^a Jefferson University   (United States)

^b Wyeth   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d SRI   (United States)

^e BIOQUAL INC   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

DNA Vaccines; HIV 1; IL 12; Macaque; SHIV

Indexed keywords

CD11B ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; DNA VACCINE; GAG PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 8; STAT1 PROTEIN; VIRUS ENVELOPE PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELLULAR IMMUNITY; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; LYMPHOCYTE ACTIVATION; MACACA; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS;

ANIMALS; FLOW CYTOMETRY; GENE PRODUCTS, ENV; GENE PRODUCTS, GAG; GENE PRODUCTS, POL; HUMANS; IMMUNITY, CELLULAR; INTERFERON TYPE II; INTERLEUKIN-12; MACACA FASCICULARIS; PLASMIDS; RANDOM ALLOCATION; RETROVIRIDAE PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, DNA;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MACACA; SIMIAN-HUMAN IMMUNODEFICIENCY VIRUS;

EID: 34547134501     PISSN: 00472565     EISSN: 16000684     Source Type: Journal    
DOI: 10.1111/j.1600-0684.2007.00245.x     Document Type: Conference Paper

References (39)

1. Ahrens D, Koch AE, Pope RM, Stein- Picarella M, Niedbala MJ: Arthritis Rheum 1996; 39: 1576-87.
2. Barouch DH, Craiu A, Kuroda MJ, Schmitz JE, Zheng XX, Santra S, Frost JD, Krivulka GR, Lifton MA, Crabbs CL, Heidecker G, Perry HC, Davies ME, Xie H, Nickerson CE, Steenbeke TD, Lord CI, Montefiori DC, Strom TB, Shiver JW, Lewis MG, Letvin NL: Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. PNAS, 2000; 97: 4192-7.
3. Barouch DH, Pau MG, Custers JH, Koudstaal W, Kostense S, Havenga MJ, Truitt DM, Sumida SM, Kishko MG, Arthur JC, Korioth-Schmitz B, Newberg MH, Gorgone DA, Lifton MA, Panicali DL, Nabel GJ, Letvin NL, Goudsmit J: Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity. J Immunol 2004; 172: 6290-7.
4. Barouch DH, Santra S, Schmitz JE, Kuroda MJ, Fu TM, Wagner W, Bilska M, Craiu A, Zheng XX, Krivulka GR, Beaudry K, Lifton MA, Nickerson CE, Trigona WL, Punt K, Freed DC, Guan L, Dubey S, Casimiro D, Simon A, Davies ME, Chastain M, Strom TB, Gelman RS, Montefiori DC, Lewis MG, Emini EA, Shiver JW, Letvin NL: Control of viremia and prevention of clinical AIDS in Rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000; 290: 486-92.
5. Boyer JD, Chattergoon M, Ugen K, Shah A, Bennett M, Cohen A, Nyland S, Lacy K, Bagarazzi M, Higgins T, Baine Y, Ciccarelli R, Ginsberg R, MacGregor R, Weiner DB: Enhancement of Cellular Immune Response in HIV-1 Seropositive Individuals: A DNA-based trial. Clinical Immunology 1999; 90: 100-7.
6. Boyer JD, Cohen AD, Vogt S, Schumann K, Nath B, Ahn L, Lacy K, Bagarazzi ML, Higgins TJ, Baine Y, Ciccarelli, R, Ginsberg R, MacGregor RR, Weiner DB: Vaccination of seronegative volunteers with a human immunodeficiency virus type 1 env/rev DNA vaccine induces antigen-specific proliferation and lymphocyte production of beta-chemokines. J Infect Dis 2000; 181: 476-83.
7. Boyer JD, Robinson TM, Kutzler MA, Parkinson R, Calarota S, Sidhu M, Lewis M, Pavlakis GN, Felber BK, Weiner DB: SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomologous macaques. J Med Primatol, 2005; 34: 262-70.
8. Calarota S, Bratt G, Nordlund S, Hinkula J, Leandersson AC, Sandström E, Wahren B: Cellular cytotoxicity induced by DNA vaccination of HIV-1 infected patients. Lancet 1998; 351: 1320-5.
9. Cao H, Kanki P, Sankale JL, Dieng-Sarr A, Mazzara GP, Kalams SA, Korber B, Mboup S, Walker BD: Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus type 1 clades: Implications for vaccine development. J Virol 1997; 71: 8615-23.
10. Chen Q, Vansant G, Oades K, Pickering M, Wei JS, Song YK, Montforte J, Khan J: J Med Diagn 2007; 9: 80-8.
11. Egan MA, Chong SY, Rose NF, Megati S, Lopez KJ, Schadeck EB, Johnson JE, Masood A, Piacente P, Druilhet RE, Barras PW, Hasselschwert DL, Reilly P, Mishkin EM, Montefiori DC, Lewis MG, Clarke DK, Hendry RM, Marx PA, Eldridge JH, Udem SA, Israel ZR, Rose JK: Immunogenicity of Attenuated Vesicular Stomatitis Virus Vector Expressing HIV Type 1 Env and SIV gag Proteins: Comparison of Intranasal and Intramuscular Vaccination Routes. AIDS 2005; 20: 989-1004.
12. El-Shabrawi YG, Christen WG, Foster SC: Curr Eye Res 2000; 20: 211-4.
13. Evans DT, Bricker JE, Desrosiers RC: A novel approach for producing lentiviruses that are limited to a single cycle of infection. J Virol 2004; 78: 11715-25.
14. Faber-Elmann A, Sthoeger Z, Tcherniack A, Dayan M, Mozes E: Clin Exp Immunol 2002; 127: 393-8.
15. Fultz PN, Stallworth J, Porter D, Novak M, Anderson MJ, Morrow CD: Immunogenicity in pig-tailed macaques of poliovirus replicons expressing HIV-1 and SIV antigens and protection against SHIV-89.6P disease. Virology 2003; 315: 425-37.
16. Johnson PR, Schnepp BC, Connell MJ, Rohne D, Robinson S, Krivulka GR, Lord CI, Zinn R, Montefiori DC, Letvin NL, Clark KR: Novel adeno-associated virus vector restricts replication of simian immunodeficiency virus in macaques. J Virology 2005; 79: 955-65.
17. Kim JJ, Ayyavoo V, Bagarazzi ML, Chattergoon M, Boyer JD, Wang B, Weiner DB: Development of a multicomponent candidate vaccine for HIV-1. Vaccine 1997; 15: 879-83.
18. Kim JJ, Bagarazzi ML, Trivedi N, Hu Y, Kazahaya K, Wilson DM, Ciccarelli R, Chattergoon MA, Dang K, Mahalingam S, Chalian AA, Agadjanyan MG, Boyer JD, Wang B, Weiner DB: Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat Biotechnol 1997; 15: 641-646.
19. Kim JJ, Nottingham LK, Sin JI, Tsai A, Morrison L, Oh J, Dang K, Hu Y, Kazahaya K, Bennett M, Dentchev T, Wilson DM, Chalian AA, Boyer JD, Aganjanyan NG, Weiner DB: CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. J Clin Invest 1998; 102: 1112-24.
20. Kim JJ, Trivedi NN, Nottingham LK, Morrison L, Tsai A, Hu Y, Mahalingam S, Dang K, Ahn L, Doyle NK, Wilson DM, Chattergoon MA, Chalian AA, Boyer JD, Agadjanyan MG, Weiner DB: Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. Eur J Immunol 1998; 28: 1089-1103.
21. Kim JJ, Ayyavoo V, Bagarazzi ML, Chattergoon M, Boyer JD, Wang B, Weiner DB: Development of a multicomponent candidate vaccine for HIV-1. Vaccine 1997; 15: 879-883.
22. Konttinen YT, Halinen S, Hanemaaijer R, Sorsa T, Hietanen J, Ceponis A, Xu JW, Manthorpe R, Whittington J, Larsson A, Salo T, Kjeldsen L, Stenman UH, Eisen AZ: Matrix metalloproteinase (mmp)-9 type IV collagenase/gelatinase implicated in the pathogenesis of Sjogren's syndrome. Matrix Biol 1998; 17: 335-347.
23. Koopman G, Mortier D, Hofman S, Niphuis H, Fagrouch Z, Norley S, Sutter G, Liljestrom P, Heeney JL: Vaccine protection from CD4+ T-cell loss caused by simian immunodeficiency virus (SIV) mac251 is afforded by sequential immunization with three unrelated vaccine vectors encoding multiple SIV antigens. J Gen Virol 2004; 85(Pt 10): 2915-24.
24. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol, 1994; 68: 4650-5.
25. Letvin NL, Huang Y, Chakrabarti BK, Xu L, Seaman MS, Beaudry K, Korioth-Schmitz B, Yu F, Rohne D, Martin KL, Miura A, Kong WP, Yang ZY, Gelman RS, Golubeva OG, Montefiori DC, Mascola JR, Nabel GJ: Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys. J Virol 2004; 78: 7490-7.
26. MacGregor RR, Boyer JD, Ugen KE, Lacy KE, Bagarazzi ML, Chattergoon M, Baine Y, Higgins T, Ciccarelli R, Coney L, Ginsberg R, Weiner DB: First Human Trial of a DNA-Based Vaccine for the Treatment of HIV-1 Infection: Safety and Host Responses. J Infect Dis 1998; 178: 92-100.
27. Makitalo B, Lundholm P, Hinkula J, Nilsson C, Karlen K, Morner A, Sutter G, Erfle V, Heeney JL, Wahren B, Biberfeld G, Thorstensson R: Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. J Gen Virol 2004; 85: 2407-19.
28. Matano T, Kobayashi M, Igarashi H, Takeda A, Nakamura H, Kano M, Sugimoto C, Mori K, Iida A, Hirata T, Hasegawa M, Yuasa T, Miyazawa M, Takahashi Y, Yasunami M, Kimura A, O'Connor DH, Watkins DI, Nagai Y: Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med 2004; 199: 1709-18.
29. Mwau M, Cebere I, Sutton J, Chikoti P, Winstone N, Wee EG, Beattie T, Chen YH, Dorrell L, McShane H, Schmidt C, Brooks M, Patel S, Roberts J, Conlon C, Rowland-Jones SL, Bwayo JJ, McMichael AJ, Hanke T: A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 2004; 85: 911-9.
30. Nacsa J, Radaelli A, Edghill-Smith Y, Venzon D, Tsai WP, Morghen Cde G, Panicali D, Tartaglia J, Franchini G: Avipox-based simian immunodeficiency virus (SIV) vaccines elicit a high frequency of SIV-specific CD4+ and CD8+ T-cell responses in vaccinia-experienced SIVmac251-infected macaques. Vaccine, 2004; 22 (5-6): 597-606.
31. Nappi F, Schneider R, Zolotukhin A, Smulevitch S, Michalowski D, Bear J, Felber BK, Pavlakis GN: Identification of a novel posttranscriptional regulatory element by using a rev- and RRE-mutated human immunodeficiency virus type 1 DNA proviral clone as a molecular trap. J Virol 2001; 10: 4558-69.
32. Paterson Y, Johnson RS: Progress towards the use of Listeria monocytogenes as a live bacterial vaccine vector for the delivery of HIV antigens. Expert Rev Vaccines 2004; 3: S119-34.
33. Rinaldo C, Huang XL, Fan ZF, Ding M, Beltz L, Logar A, Panicali D, Mazzara G, Liebmann J, Cottrill M: High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol, 1995; 69: 5838-42.
34. Rowland-Jones SL, Dong T, Dorrell L, Ogg G, Hansasuta P, Krausa P, Kimani J, Sabally S, Ariyoshi K, Oyugi J, MacDonald KS, Bwayo J, Whittle H, Plummer FA, McMichael AJ: Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly-exposed persistently seronegative donors. Immunol Lett 1999; 66: 9-14.
35. Rowland-Jones SL, Nixon DF, Aldhous MC, Gotch F, Ariyoshi K, Hallam N, Kroll JS, Froebel K, McMichael A: HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant. Lancet, 1993; 341: 860-1.
36. Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S, Whitby D, Sabally S, Gallimore A, Corrah T, Takiguchi M, Schultz T, McMichael A, Whittle H: HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995; 1: 59-64.
37. Shedlock DJA Weiner DB: DNA vaccination: antigen presentation and the induction of immunity. J Leukoc Biol 2000; 68: 793-806.
38. Sin JI, Kim JJ, Zhang D, Weiner DB: Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo. Hum Gene Ther 2001; 12: 1091-102.
39. Wang SW, Bertley FM, Kozlowski PA, Herrmann L, Manson K, Mazzara G, Piatak M, Johnson RP, Carville A, Mansfield K, Aldovini A: An SHIV DNA/ MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS. AIDS Res Hum Retroviruses 2004; 20: 846-859.